Valuation: Nectar Lifesciences Limited

Market Cap 1.81B 18.76M 16.48M 15.32M 14.06M 26.42M 26.83M 182M 71.09M 888M 70.43M 68.91M 3.07B P/E 2024
137x
P/E 2025 -4.53x
Enterprise Value 7.43B 77.15M 67.76M 63.01M 57.82M 109M 110M 748M 292M 3.65B 290M 283M 12.63B EV / Sales 2024
0.77x
EV / Sales 2025 0.64x
Free-Float
44.34%
Yield 2024 *
-
Yield 2025 -
07-11 Nectar Lifesciences Limited Announces Change in Registered Office Address CI
05-30 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
03-05 Nectar Lifesciences Limited completed the acquisition of Avensis Exports Private Limited. CI
03-02 Nectar Lifesciences to acquire 100% paid-up equity share capital of Avensis Exports RE
03-01 Nectar Lifesciences Limited agreed to acquire Avensis Exports Private Limited for INR 2.5 million. CI
01-23 Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-15 Tranche Update on Nectar Lifesciences Limited's Equity Buyback Plan announced on December 3, 2025. CI
01-05 Nectar Lifesciences Limited's Equity Buyback announced on May 6, 2023, has closed with 30,000,000 shares, representing 13.38% for INR 810 million. CI
12-19 Capnest Health Care Private Limited entered into Business Transfer agreement to acquire Empty Hard Gelatin Capsule unit at Bhatoli from Nectar Lifesciences Limited for approximately INR 200 million. CI
12-03 Nectar Lifesciences approves buyback of shares valued at 810 million rupees RE
12-03 Nectar Lifesciences Limited Appoints Sushil Kapoor as Additional Director and Whole-Time Director, Effective December 4, 2025 CI
12-03 Nectar Lifesciences Limited announces an Equity Buyback for 30,000,000 shares, representing 13.38% for INR 810 million. CI
12-02 Nectar Lifesciences Limited authorizes a Buyback Plan. CI
1 day-0.58%
1 week-5.07%
Current month-10.98%
1 month-10.75%
3 months-12.64%
6 months-29.55%
Current year-46.93%
1 week 10.21
Extreme 10.21
11.03
1 month 10.21
Extreme 10.21
11.99
Current year 9.3
Extreme 9.3
20.9
1 year 9.3
Extreme 9.3
22.4
3 years 9.3
Extreme 9.3
56.5
5 years 9.3
Extreme 9.3
56.5
10 years 7.1
Extreme 7.1
56.5
Manager TitleAgeSince
Director of Finance/CFO 68 13/11/2022
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 26/06/1995
Director/Board Member 69 10/02/2019
Director/Board Member 75 20/09/2021
Date Insider Type Main position Quantity % Market Cap.
19/12/24 Buy 400,000 0.1784%
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%-5.07%-40.15%-51.87% 20.78M
-0.66%+0.44%+14.72%+76.40% 48.36B
+2.20%+1.41%+61.04%+111.43% 35.8B
+1.26%-0.57%-5.20%+34.48% 11.83B
-0.46%-3.06%+14.15%+80.63% 11.48B
-0.37%-0.37%+37.89%+137.78% 9.01B
+1.52%+0.39%+48.79%-5.82% 6.99B
-0.17%-2.92%+13.13%+30.45% 6.7B
-0.59%-1.95%+2.23%+178.07% 6.42B
-7.92%-13.61%-34.97%-4.08% 5.3B
Average -0.58%-2.41%+11.16%+58.75% 14.19B
Weighted average by Cap. +0.12%-0.45%+25.34%+81.34%

Financials

2024 2025
Net sales 16.85B 175M 154M 143M 131M 246M 250M 1.7B 663M 8.28B 657M 643M 28.63B 16.7B 173M 152M 142M 130M 244M 248M 1.68B 657M 8.21B 651M 637M 28.39B
Net income 49.95M 519K 456K 424K 389K 730K 742K 5.03M 1.97M 24.56M 1.95M 1.91M 84.91M -1.14B -11.8M -10.37M -9.64M -8.85M -16.62M -16.88M -114M -44.73M -559M -44.32M -43.36M -1.93B
Net Debt 6.15B 63.89M 56.11M 52.18M 47.88M 89.97M 91.36M 620M 242M 3.02B 240M 235M 10.46B 5.62B 58.39M 51.28M 47.69M 43.76M 82.23M 83.49M 566M 221M 2.76B 219M 214M 9.56B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
1,786
Date Price Change Volume
24/07/26 ₹10.30 -0.58% 73,731
23/07/26 ₹10.36 -1.80% 76,356
22/07/26 ₹10.55 -1.40% 84,687
21/07/26 ₹10.70 -0.93% 71,281
20/07/26 ₹10.80 -0.46% 70,264
  1. Stock Market
  2. Stocks
  3. NECLIFE Stock